Table 2:

Summary of Studies Examining GeneSight Pharmacogenomic Testing

Author, Year	Study Design	Study Conclusion
Hall-Flavin et al, 201228	Nonrandomized, open-label, consecutive comparative cohort study comparing unguided treatment as usual and guided care with combinatorial genomic testing using GeneSight	Patients in the group guided by GeneSight had greater reduction in depression scores than patients who received unguided treatment
Hall-Flavin et al, 201327	Nonrandomized, open-label, consecutive comparative cohort study comparing unguided treatment as usual and guided care with combinatorial genomic testing using GeneSight	Patients had improved depression outcomes when GeneSight was used for pharmacogenomic testing
Winner et al, 201329	Double-blind randomized controlled trial comparing unguided treatment as usual and guided care with combinatorial genomic testing using GeneSight	Patients who received treatment guided by GeneSight were more likely to respond to therapy, and patients with severe gene-drug interactions who were switched to a more gene-suitable medication had the greatest improvement in depressive symptoms
Winner et al, 201530	Controlled, propensity-matched, prospective cohort study evaluating medication regimens between patients who received guided care with GeneSight vs. usual care, with a focus on cost comparison	Combinatorial testing improved adherence and led to cost savings